Patent · US Active

Structure-based peptide inhibitors of α-synuclein aggregation

US11390646B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

David S. Eisenberg · Los Angeles, US
Smriti Sangwan · Los Angeles, US
Lin Jiang · Los Angeles, US

Key dates

Filing date	May 26, 2020
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Jul 1, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/2835
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to inhibitory peptides which bind to α-synuclein molecules and inhibit α-synuclein amyloidogenic aggregation, α-synuclein cytotoxicity, and spread of α-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.